Neurocrine Biosciences Inc. (1NBIX)
MTA
131.15
-2.05 (-1.54%)
Closed
Aug 24, 2026
Day's Range
130.55136.45
52 wk Range
101.00159.45
Financial Statements - 1NBIX - Neurocrine Biosciences Inc.
Revenue
2.86B▲ 44.5%
Net Income
478.60M▲ 66.9%Net Margin 16.7%
EBITDA
688.00M▲ 16.8%
Free Cash Flow
748.70M▲ 59.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 2.86B | 1.97B |
| Cost of Goods | 52.10M | 28.57M |
| Gross Profit | 2.80B | 1.95B |
 Operating Expense | - | - |
| Operating Income | 636.50M | 489.91M |
| Non-Operating Interest | - | - |
| Other Income Expense | -21.40M | -51.59M |
| Pre Tax Income | 705.40M | 408.40M |
| Income Tax | 226.80M | 121.59M |
| Net Income | 478.60M | 286.80M |
| EPS Basic | 4.81 | 3.4 |
| EPS Diluted | 4.67 | 3.29 |
| Basic Shares Outstanding | 99.50M | 84.36M |
| Diluted Shares Outstanding | 99.50M | 84.36M |
| Ebit | 636.50M | 514.78M |
| Ebitda | 688M | 589.15M |
| Net Income Continuous Operations | 478.60M | 286.80M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
